Literature DB >> 24195481

Recent developments in tuberculosis vaccines.

Dessislava Marinova1, Jesus Gonzalo-Asensio, Nacho Aguilo, Carlos Martin.   

Abstract

Substantial efforts have been made over the past decade to develop vaccines against tuberculosis. We review recent developments in tuberculosis vaccines in the global portfolio, including those designed for use in a prophylactic setting, either alone or as boosts to Bacille Calmette-Guérin, and therapeutic vaccines designed to improve chemotherapy. While there is no doubt that progress is still being made, there are limitations to our animal model screening processes, which are further amplified by the lack of understanding of the immunological responses involved and the precise type of long-lived immunity that new vaccines need to induce. The challenge ahead is to optimize the planning for advanced clinical trials in poor endemic settings, which could be greatly facilitated by identifying correlates of protection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24195481     DOI: 10.1586/14760584.2013.856765

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  11 in total

Review 1.  Current trends in tuberculosis vaccine.

Authors:  J S V Soundarya; Uma Devi Ranganathan; Srikanth P Tripathy
Journal:  Med J Armed Forces India       Date:  2019-01-18

2.  Toward a human vaccines project.

Authors:  Wayne C Koff; Ian D Gust; Stanley A Plotkin
Journal:  Nat Immunol       Date:  2014-07       Impact factor: 25.606

3.  Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination.

Authors:  Nacho Aguilo; Ana Maria Toledo; Eva Maria Lopez-Roman; Esther Perez-Herran; Eamonn Gormley; Joaquin Rullas-Trincado; Iñigo Angulo-Barturen; Carlos Martin
Journal:  Clin Vaccine Immunol       Date:  2014-02-05

4.  Potential impact of spatially targeted adult tuberculosis vaccine in Gujarat, India.

Authors:  Sourya Shrestha; Susmita Chatterjee; Krishna D Rao; David W Dowdy
Journal:  J R Soc Interface       Date:  2016-03       Impact factor: 4.118

5.  Integrative immunoinformatics for Mycobacterial diseases in R platform.

Authors:  Rupanjali Chaudhuri; Deepika Kulshreshtha; Muthukurussi Varieth Raghunandanan; Srinivasan Ramachandran
Journal:  Syst Synth Biol       Date:  2014-02-15

Review 6.  The current status, challenges, and future developments of new tuberculosis vaccines.

Authors:  Wenping Gong; Yan Liang; Xueqiong Wu
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452

7.  MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice.

Authors:  Nacho Aguilo; Santiago Uranga; Dessislava Marinova; Marta Monzon; Juan Badiola; Carlos Martin
Journal:  Tuberculosis (Edinb)       Date:  2015-11-30       Impact factor: 3.131

8.  On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines.

Authors:  Sergio Arregui; Joaquín Sanz; Dessislava Marinova; Carlos Martín; Yamir Moreno
Journal:  PeerJ       Date:  2016-02-11       Impact factor: 2.984

9.  Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis.

Authors:  Nacho Aguilo; Jesus Gonzalo-Asensio; Samuel Alvarez-Arguedas; Dessislava Marinova; Ana Belen Gomez; Santiago Uranga; Ralf Spallek; Mahavir Singh; Regine Audran; François Spertini; Carlos Martin
Journal:  Nat Commun       Date:  2017-07-14       Impact factor: 14.919

Review 10.  Considerations for the rational design of a Chlamydia vaccine.

Authors:  Steven Liang; David Bulir; Charu Kaushic; James Mahony
Journal:  Hum Vaccin Immunother       Date:  2016-11-11       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.